awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6
Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
P2860
Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35073758-B0F5954D-414E-4676-B8E2-D61200D8FBC6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2fb869d6138729053d8812f9958e68aac5debbd7
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer